Dr. Doris Fuertinger discusses the future impact of novel therapeutic interventions on populations with kidney disease.

Dr. Hanjie Zhang discusses the benefits and risks of Generative AI in healthcare.

Dr. Giovanni Strippoli discusses how the CONVINCE study results will contribute to reaching a higher level of certainty regarding the comparative efficacy of hemodiafiltration versus HD in people with end-stage kidney disease.

Michelle Carver, Chief Nursing Officer and Senior Vice President of Nursing and Clinical Services at Fresenius Kidney Care, discusses the benefits and challenges of patients dialyzing at home.

Manuela Stauss-Grabo, PhD, leads the Global Biomedical Evidence Generation Team within Fresenius Medical Care’s Global Medical Office.

Krister Cromm, Fresenius Medical Care’s Director Person-Centered Outcomes Research, discuss the company’s evolution from disease-centered to person-centered integrated trial design.

Luca Neri, senior director of clinical advanced analytics at Fresenius Medical Care, discusses Anemia Management with AI and computational modeling.

Prof. Peter Blankestijn discusses the results of the multicenter CONVINCE Study including how the use of hemodiafiltration impacts patient morbidity and all-cause mortality as well as patient-reported outcomes.

Anjana Harve, Fresenius Medical Care’s Chief Information Office, talks about cybersecurity and the use of health information systems to improve the quality of care for patients.

Brigitte Schiller, Fresenius Medical Care’s senior vice president for home therapies, discusses the ecosystem and opportunities for patients to do dialysis in their own home.

David Rhew, Microsoft’s Chief Medical Officer and Vice President of Healthcare, discusses ChatGPT’s uses in healthcare.

Dr. Isaac “Zak” Kohane, Chair of the Department of Biomedical Informatics at Harvard Medical School discusses the adoption of artificial intelligence and machine learning in healthcare.

Jochen Raimann, the director of data analytics for the Renal Research Institute, discusses the Two-Plus Study and its potential benefits for patients.

Dr. Frank Maddux discusses the potential impact of GLP-1 Rezeptor agonists and SGLT-2 Inhibitors on chronic kidney disease care.

Dr. Reshma Kewalramani, CEO of Vertex Pharmaceuticals discusses the company’s research into the underlying cause of APOL1-mediated kidney disease.

Learn how documenting patient care, allows participating providers to improve patient outcomes through care coordination.

Dr. Laura Niklason, Founder and CEO of Humacyte, discusses this promising technology and its recent deployment as humanitarian aid for repairing vascular trauma in Ukraine.

In this episode of GMO Dialogues, Robert Sepucha, CEO of InterWell health talks about how this legislation changed the trajectory of kidney disease care in the United States, and led to value-based care models of today.

Dr. Len Usvyat, the Global Medical Office’s head of Clinical Advanced Analytics, talks about how real-world data generated by devices is used to improve the care of people living with kidney disease.

Dr. Miriam Huntley talks about improving infectious disease diagnosis and treatment, genomic sequencing, and machine learning to solve antibiotic resistance.

Dr. Sumit Mohan joins this episode to discuss the importance of kidney transplantation and strategies to address inequities in kidney transplantation access.

Dr. Maria Mercedes Resk, Medical Director for Fresenius Medical Care CARICAM, discusses cardioprotection and personalizing kidney replacement therapy.

Dr. Kirsten Johansen discusses the racial and ethnic disparities in CKD, ESRD, and the access to treatment of these conditions according to the USRDS.

Dr. Michael Anger joins this episode to discuss how SGLT-2 inhibitors can be used earlier with kidney disease patients and improve overall patient health.

Krister Cromm, FMCNA's Director of Patient Experience, discusses improving patient health by including patient reported outcomes in clinical trials.

Dr. Jennifer Flythe discusses patient-related outcome measures and how they can improve the quality of kidney disease patient care.

Dr. Felicia Speed, VP of Social Work Services at FMCNA, discusses her work to develop mental health modules for healthcare professionals since COVID-19.

Nephrologist Kolitha Basnayake discusses how quality improvement programs must address barriers to shared hemodialysis care for the individual.

Nephrologist Kolitha Basnayake discusses how quality improvement programs must address barriers to shared hemodialysis care for the individual.

Dr. Nilufar Mohebbi, discusses treating metabolic acidosis in patients, which can delay the progression of chronic kidney disease.

Race is currently one factor used in GFR equations. Nephrologist Nwamaka Eneanya wonders if its inclusion may contribute to systemic racism in medicine.

Fresenius Medical Care developed its own ultrafiltration controller for fluid management. Dr. Lemuel Rivera Fuentes discusses this breakthrough innovation.

Real-world evidence can complement existing research in gaining new and valuable insights that improve kidney disease care with Dr. Ficociello and Dr. Winter.

Improving vascular access affects outcomes for people on hemodialysis. Dr. Latif discusses improving patient outcomes by addressing opportunities in vascular access.

Dr. Hippen discusses the challenges facing global transplant and why transplantation remains a vital therapy option for people with advanced kidney disease.

Cardiovascular disease is the number one cause of death for people with kidney disease. Learn why cardiac disease is such a problem in kidney failure patients

Combining clinical and genetic data from patients, scientists can understand how to make a more precise diagnosis of kidney disease in individualized care.

Frenova Renal Research is building a Genomics Registry to analyze genetic sequencing data from chronic kidney disease patients worldwide. Listen now.

Social determinants of health such as food insecurity, have a profound impact on people living with chronic kidney disease and other related conditions.

Investigate the relationship between human health and climate change events that can increase the risk of kidney disease and respiratory illness.

Metabolomic signatures can be used to deliver more personal, precise care for patients living with kidney disease.

Dr. Matthias Rose discusses the integration of patient-reported outcomes into the CONVINCE study.

Dr. Vivekanand Jha, Executive Director, of The George Institute for Global Health in India discusses health inequality and how it manifests in communities.

Dr. Shelly Nash, Senior Vice President and Chief Medical Information Officer for the Global Medical Office at Fresenius Medical Care, discusses the benefits of connected health.

In this episode of Dialogues, we continue our look at Translating Science Into Medicine by talking with Dr. Doris Fuertinger, Director of Biomathematical Modeling and Simulation at Fresenius Medical Care, and a pioneer in the concept of virtual clinical trials.